Scholar Rock Holding (SRRK) EBITDA (2017 - 2026)
Scholar Rock Holding's quarterly EBITDA came in at -$104.9 million in Q1 2026, down 40.35% year-on-year from -$175.9 million in Q1 2025, and down 15.31% quarter-over-quarter from -$91.0 million in Q4 2025.
Scholar Rock Holding has reported EBITDA for 10 years, with the latest figure at -$104.9 million in Q1 2026.
- For the quarter ending Q1 2026, EBITDA fell 40.35% year-over-year to -$104.9 million; the trailing twelve-month figure through Mar 2026 stood at -$408.2 million (down 54.62% YoY), and the FY2025 full-year result was -$378.0 million, down 53.52% from the prior year.
- EBITDA for Q1 2026 stood at -$104.9 million, down from -$91.0 million in the prior quarter.
- The five-year high for EBITDA was -$8.1 million in Q1 2022, with the low at -$110.1 million in Q2 2025.
- Average EBITDA over 5 years is -$60.5 million, with a median of -$57.0 million recorded in 2024.
- Year-over-year, EBITDA soared 70.82% in 2022 and sank 381.27% in 2023.
- Tracing SRRK's EBITDA over 5 years: stood at -$39.2 million in 2022, then decreased by 17.37% to -$46.0 million in 2023, then sank by 44.36% to -$66.4 million in 2024, then slumped by 36.98% to -$91.0 million in 2025, then decreased by 15.31% to -$104.9 million in 2026.
- The last three EBITDA figures came in at -$104.9 million (Q1 2026), -$91.0 million (Q4 2025), and -$102.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -13.63 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.44 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 661.60 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 201.19 Mn |
| 10 | Scholar Rock Holding | 500.61 Mn | 20.67 Mn | - | -104.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -104.91 Mn |
| Dec 31, 2025 | -90.99 Mn |
| Sep 30, 2025 | -102.16 Mn |
| Jun 30, 2025 | -110.10 Mn |
| Mar 31, 2025 | -74.75 Mn |
| Dec 31, 2024 | -66.42 Mn |
| Sep 30, 2024 | -64.30 Mn |
| Jun 30, 2024 | -58.51 Mn |
| Mar 31, 2024 | -57.00 Mn |
| Dec 31, 2023 | -46.01 Mn |
| Sep 30, 2023 | -42.32 Mn |
| Jun 30, 2023 | -37.66 Mn |
| Mar 31, 2023 | -38.82 Mn |
| Dec 31, 2022 | -39.20 Mn |
| Sep 30, 2022 | -44.15 Mn |
| Jun 30, 2022 | -43.93 Mn |
| Mar 31, 2022 | -8.07 Mn |
| Dec 31, 2021 | -35.95 Mn |
| Sep 30, 2021 | -37.52 Mn |
| Jun 30, 2021 | -30.72 Mn |
| Mar 31, 2021 | -27.65 Mn |
| Dec 31, 2020 | -26.58 Mn |
| Sep 30, 2020 | -23.61 Mn |
| Jun 30, 2020 | -19.47 Mn |
| Mar 31, 2020 | -16.87 Mn |
| Dec 31, 2019 | -11.56 Mn |
| Sep 30, 2019 | -16.18 Mn |
| Jun 30, 2019 | -12.48 Mn |
| Mar 31, 2019 | -10.73 Mn |
| Dec 31, 2018 | -14.97 Mn |
| Sep 30, 2018 | -10.76 Mn |
| Jun 30, 2018 | -14.71 Mn |
| Mar 31, 2018 | -8.89 Mn |
| Dec 31, 2017 | -8.45 Mn |
| Sep 30, 2017 | -5.92 Mn |
| Jun 30, 2017 | -5.88 Mn |